Abilify as an Adjunctive Treatment for Refractory Depression
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical
antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI)
antidepressant treatment for depressed outpatients who are not responding fully to SSRI
treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of
treatment with Aripiprazole and SSRI medication.